To investigate this possibility, we analyzed expression data from PDX breast cancer models originating from BRCA1 mutation carriers whose sensitivity to olaparib had also been characterized ((Cruz et al, 2018) and Appendix Fig S8). The gene discussed is BRCA1; the disease is breast carcinoma.